SCHEDULE 13G/A: BlackRock Amends Stake in AngioDynamics, Disclosing 9.7% Ownership

BlackRock, Inc. has filed an amended Schedule 13G, revealing its beneficial ownership of 9.7% of AngioDynamics Inc.'s common stock as of December 31, 2024.

Summary

• BlackRock, Inc. has filed Amendment No. 7 to its Schedule 13G, detailing its beneficial ownership in ANGIODYNAMICS INC.
• As of December 31, 2024, BlackRock beneficially owns an aggregate of 3,941,630 shares of ANGIODYNAMICS INC common stock.
• This ownership represents 9.7% of the total outstanding common stock of ANGIODYNAMICS INC.
• BlackRock holds sole voting power over 3,746,186 shares and sole dispositive power over 3,941,630 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• Several BlackRock subsidiaries are identified as entities that acquired the security, including BlackRock Investment Management, LLC, which beneficially owns 5% or greater of the outstanding shares.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing an ownership stake. It contains factual information and no subjective language that would indicate positive or negative sentiment regarding the issuer's performance or prospects.

Future Outlook

The document is an ownership disclosure and does not provide any forward-looking statements or guidance regarding AngioDynamics Inc.'s future performance or outlook.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

This Schedule 13G filing indicates a significant passive institutional investment by BlackRock, one of the world's largest asset managers, in AngioDynamics Inc., a company operating in the medical device sector. Such filings are routine disclosures of substantial ownership stakes by institutional investors, reflecting their portfolio allocation decisions rather than direct strategic involvement in the issuer's operations. It signals continued institutional interest in the medical technology industry.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory requirement for institutional investors acquiring more than 5% of a company's stock.
• It does not contain information that allows for a comparison of AngioDynamics Inc.'s performance against industry benchmarks or specific comparable companies/projects.
• The filing itself is a compliance document for BlackRock's investment activities.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming BlackRock's continued passive investment in AngioDynamics Inc.

Next Steps

• The document does not outline any specific future actions, events, or milestones for AngioDynamics Inc. or BlackRock beyond the routine compliance of filing this amendment.

Key Dates

Keywords

BlackRock, AngioDynamics, Schedule 13G, beneficial ownership, institutional investment, common stock, SEC filing, ownership disclosure, medical devices